Wuzhou Pharmaceutical Co., Ltd. and dema Co., Ltd. are still in the phase II clinical stage of FDA

At the annual performance presentation meeting on May 8, Zhongheng group said that Wuzhou pharmaceutical, a subsidiary of Zhongheng group, cooperated with dema company to carry out the FDA clinical certification of desquametol in the United States, which is still in the second stage If the certification is passed, it will have a greater positive impact on the development of the company At present, the progress of cooperation between China and hengdema on the removal of water cresol is lower than expected In October 2012, China Evergrande group's Wuzhou Pharmaceutical Co., Ltd signed a joint development agreement with Canada dema Co., Ltd to promote the listing of desquametol in China, the United States, Canada and Europe Its indications include glioma and others, and to provide clinical and non clinical data to support China Evergrande to obtain SFDA approval for the treatment of multiformity of desquametol for injection New indications of glioblastoma Compared with the original expectation of dema company on the time to market of the drug, the progress of cooperation between the two sides has been far behind, and there is no progress in the cooperation of clinical trials of new indications in China Dema has expected that the drug treatment of gliomas with desolventol and Avastin will be completed by FDA around 2014 in the public information released by dema The clinical, registration and application work entered the commercialization stage in the next year; the clinical, registration and application work of FDA for glioblastoma treated by desquametol as a drug not combined with Avastin was completed in 2015, and entered the commercialization stage in the next year.